Feasibility of Intravaginal Artesunate as Adjuvant HPV & Cervical Precancer Treatment in Kenya

Inclusion Criteria * Age 25 years or older * Known HIV seropositive status * On antiretroviral therapy for \> 90 days prior to enrollment * Weight ≥50 Kg at study entry\* * Positive HPV screening test and within 4-8 weeks of thermal ablation * Ability to provide informed consent * Planning to stay within the study locale during the duration of the study (24 weeks) * Agreement to use contraception (barriers or hormonal) if of childbearing age through week 6 of the study Exclusion Criteria * Current pregnancy or breastfeeding status * Current or past history of invasive cervical cancer * History of total hysterectomy * Currently receiving systemic chemotherapy or radiation therapy for another cancer * Current use of systemic immunosuppressants or steroids (\>10 mg of prednisone or equivalent) * Current use of efavirenz antiretroviral therapy, phenytoin, carbamazepine, and rifampin * Have medical comorbidity that, in the opinion of the investigator, would interfere with study participation * Prior chemotherapy within 30 days prior to day 1 of study treatment * Male at birth